Nightingale Health’s Post

Exciting news to share: our paper on metabolomic and genomic prediction of common diseases in over 700,000 participants across three national biobanks is now published in peer reviewed form! https://lnkd.in/d_wTNhhR This study expands on previous work on how metabolomics can help predict health outcomes more accurately. Metabolomic scores complemented polygenic risk scores (PGS) for predicting the onset of many common diseases, including type 2 diabetes and cardiovascular conditions. In many cases the performance of metabolomics scores was better than PGS, which suggests that efforts to improve personalised prevention should incorporate both types of data. Furthermore, repeated measurements of metabolomic biomarkers five years apart (in a subset of participants) revealed that individuals whose scores changed saw changes in their risk. This suggests metabolomics can be a dynamic tool for tracking health improvements or deterioration due to lifestyle changes or treatments. We're thrilled to share the final version of this work. If you have questions or thoughts, we'd love to discuss them!

New Post: Could Protein Clumps Predict Age-Related Diseases? – World Pakistan - Scientists propose a “protein aggregation clock” as a new method to assess aging and health by monitoring protein clumps in cells. This concept, if developed into a diagnostic tool, could enable early detection of age-related diseases and assessment of new treatments aimed at reducing protein aggregation. The protein aggregation clock could complement existing genetic-based biological …

Risk prediction using genes and gut bacteria can improve early detection of diseases like type 2 diabetes A recent study demonstrates that risk scores, which take into account our genetic makeup and gut bacteria, can significantly enhance the prediction of diseases like type 2 diabetes and prostate cancer, beyond traditional risk factors alone. Conducted by Dr. Yang Liu and a team from the Baker Heart and Diabetes Institute, the University of Cambridge, and the Finnish Institute of Health and Welfare, this research marks one of the initial attempts to analyze the combined effect of genetics and the gut microbiome on disease risk. The study used data from over 5,670 adults and showed that adding information about our genetic risk and the composition of our gut bacteria to existing risk factors results in a more powerful prediction tool for common chronic diseases. This approach could lead to a more personalised and effective way of predicting and potentially preventing diseases like coronary artery disease, type 2 diabetes, Alzheimer's disease, and prostate cancer. Link to Study: https://lnkd.in/gvFrFKTM #guthealthmatters #functionalnutrition #microbiome

🚨 Did you know? Diabetes Mellitus is at the heart of numerous health complications, from vascular diseases to metabolic disorders. But how do we uncover these complex connections? Request pricing and learn more here: 🔗 https://lnkd.in/ePwze3YD Introducing HumanPSD – a cutting-edge tool from geneXplain GmbH that enables researchers to map disease-disease relationships🧬 This graph highlights how HumanPSD leverages common biomarkers to create intricate networks that reveal: 🔗 Connections between diseases (e.g., diabetes, cardiovascular disorders, obesity). 🧪 Shared molecular pathways and biomarkers driving these conditions. 💡 Insights into potential therapeutic targets and research directions. Why choose HumanPSD? 🔍 Powerful Insights: Understand systemic diseases holistically. 🛠️ Customizable Visualizations: Generate disease networks tailored to your research. 🌐 Broad Applications: Ideal for researchers exploring biomarkers, drug development, and precision medicine. Let’s unravel the complexity of human diseases together. 🌟 #bioinformatics #systemsbiology #researchtools #genomics #precisionmedicine #HumanPSD #geneXplain #DiabetesResearch

This is an incredible resource published in Cell by Cell Press combining data-driven analysis, personalised medicine, and drug repurposing: "Atlas of the plasma proteome in health and disease in 53,026 adults.” A fascinating observation is that in combination with other studies GDF15 emerges as a predictive biomarker for a wide range of conditions, including autoimmune disorders, incident diseases, diabetes, and mental health. Why is this so cool? Because GDF15 is linked to mitochondrial diseases and is a hallmark of energetic stress. Whereas increasing mitochondrial energy flow reduces GDF15 levels.  This means that health and the chronic diseases of the modern age are centred around the well-being of your mitos. The future of health isn’t about drugs, folks - it’s about keeping your mitochondria happy! #Proteomics #Mitochondria #PrecisionMedicine Fudan University

A new and freely available Human Gut Microbiome Atlas could help researchers and health care professionals around the world better understand how microorganisms in the gut impact disease, leading to more effective treatment. The study, published in Genome Research, is an international collaboration led by King's College London that identifies gut bacteria appearing in individuals with 23 separate diseases across 19 countries. Carried out in collaboration with MetaGenoPolis and the Science for Life Laboratory, the global study is the largest to date. By tagging clusters of microbiome features to specific diseases, the authors believe this data could help diagnose and provide individual pathways for treatment for illnesses such as colorectal cancer and Crohn's Disease. The human gut microbiome is the individual profile of bacteria and other microorganisms that live in the gut that helps perform key bodily functions, such as digestion. Recently, it has been shown to have a strong relationship with the development of a wide variety of diseases, including type two diabetes, depression and Alzheimer's disease. Until now the information that exists on microbiomes has been fragmented. While data exists on the genetic makeup of individual microbes in the gut, these are siloed dependent on specific diseases. This prevents large-scale comparative studies and doctors from tailoring treatments to work with the microbiome of their patients. https://lnkd.in/gmbB8gZq

𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐏𝐃𝐅 𝐆𝐮𝐢𝐝𝐞 𝐭𝐨 #Pharmacogenomics 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞 𝐅𝐨𝐫 𝐏𝐃𝐅: @ https://lnkd.in/gy8Ycztd The pharmacogenomics market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028. The increasing prevalence of chronic diseases is one of the most critical factors driving the growth of the market. Many older adults (>60%) suffer from two or more chronic conditions. Twin studies stated that genes can cause chronic conditions, such as cardiovascular disease (CVDs), diabetes, obesity, RA, Alzheimer's disease (AD), and depression. Using molecular genetic data from genome-wide association studies (GWAS), it is now possible to measure individual-level risks for these chronic diseases. According to the Centers for Disease Control and Prevention (CDC), in 2020, nearly 6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people had two or more chronic conditions. The increasing incidence of chronic diseases is triggering the demand of pharmacogenomic technologies for developing novel therapies. #Pharmacogenomics #PrecisionMedicine #Genomics #PersonalizedMedicine #DrugResponse #Biomarkers #Pharma #ClinicalPharmacology #HealthcareInnovation

Diabetes and lipidomics risk score --- Today, on World Diabetes Day, we would like to underline the importance of diabetes early identification. According to Lauber and Simons, combining genetic background, lipidomic profile changes, and clinical risk factors offers a more precise prediction of future type 2 diabetes (T2D) and cardiovascular disease (CVD) risk. Their research, which analyzed genomic and lipidomic data from 4067 participants, demonstrated that lipidomics risk scores significantly improve risk prediction. The study concluded that integrating lipidomics risk scores with clinical and polygenic parameters improves risk stratification for T2D and CVD. Regular lipidome monitoring could help track health status and reveal the effects of lifestyle and diet on disease risk. Read the full article here: https://lnkd.in/eeMw5zt9 #WorldDiabetesDay #DiabetesAwareness #Type2Diabetes #CardiovascularDisease #lipidomics #HealthInnovation #lipotype #research #lipid #LipidMetabolism #lipidome #MassSpectrometry #metabolism

Unlocking the Genetic Keys to Autoimmune Diseases At Vitruvion, we're dedicated to deepening the understanding of how genetics can influence health outcomes, particularly in the realm of autoimmune diseases. With advances in genomic technology, we can now identify specific genetic markers that predispose individuals to various autoimmune conditions, offering unprecedented insights into prevention and management. Why Focus on Autoimmune Diseases? Early Detection: Genomic insights can help predict susceptibility to autoimmune diseases before symptoms manifest, allowing for proactive management strategies. Personalized Treatment Plans: Understanding genetic predispositions enables health professionals to tailor treatments that are more likely to be effective for individual patients, reducing trial and error in medication and therapy choices. Preventive Strategies: By knowing genetic risk factors, individuals can make lifestyle and environmental changes that may decrease the likelihood of disease activation or progression. Embrace the potential of genomics to transform the approach to autoimmune diseases. Stay informed with Vitruvion as we explore how these insights can be integrated into clinical practice to improve patient care and outcomes. #AutoimmuneAwareness #GenomicInsights #PersonalizedMedicine #Vitruvion

Proteolethargy — the reduction in #proteinmobility induced by hyperglycemia, dyslipidemia, inflammation, genotoxic stress, endotoxins, and drug toxicity —can exacerbate #chronicdiseases such as insulin resistance, metabolic disorders, and neurodegenerative diseases. Restoring protein mobility by enhancing protein folding, degradation, and trafficking could offer a promising therapeutic strategy for these conditions. In this study, the authors demonstrated that surface-exposed cysteines play a key role in modulating protein mobility when cells are exposed to #oxidativestress and pathogenic signaling. Approximately 50% of human proteins contain at least one surface-exposed cysteine, suggesting that nearly half of the proteome could be directly susceptible to proteolethargy in high oxidative environments.